Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia Chemoimmunotherapies have become a very potent tool to achieve long-lasting remissions in chronic lymphocytic leukemia (CLL) and the addition of rituximab to fludarabine and cyclophosphamide (FCR) was the first treatment shown to increase overall survival. 1 Because alemtuzumab as a single agent is more potent than rituximab in CLL, the rationale for this study was to combine this anti-CD52 antibody with a FC chemotherapy backbone. [2] [3] [4] Figure 2. Relation between Notch signaling and the impaired osteogenic differentiation of MM-hMSCs. (a) Selected ND-hMSCs and MM-hMSCs with impaired osteogenic differentiation were cultured in OM for 7 days. Notch signaling receptors and downstream genes were measured by real-time PCR. The percentage of Notch signaling activity level after 7 days culture in OM compared with the level when cells were cultured in growth medium (GM) was shown. (b) Addition of 10 mM DAPT in GM for 48 h reduced the level of Hes1 and increased Runx2 expression for MM-hMSCs. (c) MM-hMSCs showed increased mRNA expression of bone markers by qPCR after culturing in OM supplemented with DAPT for 7 days. (d) DAPT-treated MM-hMSCs showed enhanced ALP activity after culturing in OM for 3 days. Representative results of three experiments are shown. (e) MM-hMSCs were cultured in OM supplemented with or without DAPT for 14 days. Calcium deposits were assessed by alizarin red staining. The cells treated with DAPT demonstrated increased mineralization. Original magnification, Â 100. Scale bar, 100 mm. Representative results from three experiments are shown. (f ) In 5T33MM mice, osteoblast cell number per endocordical bone surface dropped down significantly compared with naive mice. n ¼ 5/group. (g) NOTCH inhibitor DAPT treatment in naive mice. Mice were given DAPT or dimethyl sulfoxide (DMSO) intraperitoneally 10 mg/kg daily for 20 days (n ¼ 3/group). One leg was used to isolate BM and perform CFU-F assay, and the other leg was used for histomorphometric analysis. For the mice given DAPT treatment, there were significantly less MSC colonies in CFU-F assay (left panel), and meanwhile 33.4% more osteoblast cells per endocordical bone surface was observed (right panel). n ¼ 3. (h) Notch inhibitor DAPT treatment in 5T33MM mice. Mice were given DAPT or DMSO intraperitoneally 10 mg/kg daily for 20 days. One leg was used to isolate BM and evaluate tumor burden, and the other leg was used for histomorphometric analysis. We did not observe either any significant effect of DAPT on MM tumor burden (n ¼ 8/group), or on osteoblasts and bone formation (n ¼ 3/group). The data was represented as mean ± SD. *Po0.05; ***Po0.001.
Accepted article preview online 15 May 2012; advance online publication, 8 June 2012 Letters to the Editor A previous trial of fludarabine with alemtuzumab (FluCam) showed excellent results (overall response rate (ORR) 83%, complete response rate (CR) 30%) in relapsed or refractory patients, with a time to progression (TTP) of 35.6 months for all heavily pretreated patients. 5 These results have been confirmed in a large randomized phase III trial, comparing FluCam to fludarabine monotherapy in 335 patients with relapsed or refractory disease. 6 FluCam demonstrated an excellent treatment outcome and found that both progression-free survival (PFS) (23.7 months vs 16.5 months) and overall survival were significantly better with the combination treatment than with fludarabine alone. 5, 6 Therefore, the German CLL Study Group performed a prospective, multicenter, open-label, non-randomized phase II trial to investigate the safety and efficacy (ORR) of a triple combination consisting of fludarabine, cyclophosphamide and alemtuzumab (FCCam) in patients with primary high-risk (deletion 17p), relapsed or refractory CLL (EudraCT2005-003017-32).
The secondary objectives of this study were the efficacy in biological defined risk groups, duration of response, and eventfree survival (EFS), minimal residual disease (MRD) response rate, CR and toxicity. All patients who received at least one dose of study drug were included in the safety analysis.
Approval for this study was obtained from the Institutional Review Board of the University of Cologne and in accordance with an assurance filed with and approved by the Department of Health and Human Services; all patients gave written informed consent according to the Declaration of Helsinki.
FCCam was given for a total of 3 consecutive days, which was repeated every 28 days for a total of six cycles. In detail, one cycle consisted of 3 days of alemtuzumab 30 mg subcutaneously, fludarabine 25 mg/m 2 intravenously (i.v.) over 30 min and cyclophosphamide 200 mg/m 2 i.v. over 30 min; premedication, infection prophylaxis and monitoring was performed according to actual standards. 7 Diagnosis and restaging was carried out according to the 1996 National Cancer Institute (NCI) criteria. 8 Of the 61 CLL patients recruited from March 2005 to November 2008 in centers across Germany, four patients did not receive therapy owing to withdrawn consent or revision of diagnosis. A total of 57 patients received treatment, but 5 patients were not evaluable for response as 4 patients died within the first three cycles and another patient developed a secondary malignant disease.
The median age of treated patients was 63 years (36-78), with 41 male and 16 female patients. Binet stages A, B and C were seen in 13, 14 and 30 patients, respectively. Treatment indication for Binet A patients was mainly B-symptoms, but also lymphadenopathy in 11 patients, autoimmune hemolytic anemia (AIHA) in one case and fast progressing lymphocytosis in two patients with del(17p).
The median number of prior therapies was one (0-4), but five patients harboring a del(17p) received FCCam as first-line treatment. The majority was pretreated with bendamustine-or fludarabine-based regimen (n ¼ 48, 84%), 13 of them in combination with rituximab. 19 patients (33%) were refractory to the previous line of therapy.
Cytogenetic abnormalities were found in 86% of patients, with 19% of patients harboring a del(17p). The majority of patients (79%) showed an unmutated immunoglobulin variable heavy chain (IGHV) status.
A total of 57 patients received a median of five cycles and 21 patients received all six intended cycles. Reasons for early termination were hematological side effects (10 patients), early death (7 patients), progressive disease (4 patients), AIHA (1 patient) and infections (6 patients). Two patients proceeded to allogeneic transplantation without completion of all 6 cycles, one patient refused cycle 5 after achieving an early CR.
As expected, leukocytopenia and neutropenia common toxicity criteria (CTC) 13-4 were the most frequent hematological side effects (40.7%). Of two treatment-related AIHA, one resulted in a fatal event, the other was effectively treated with steroids. Thrombocytopenia CTC 13-4 affected 16 patients, 6 of whom received platelet support.
The time frame for serious adverse events (SAE) related to therapy was defined to be 6 months after the last therapy has been given. In this period, 27 patients sustained 57 SAEs, the vast majority (42 SAEs, 74%) were infectious complications, 8 of which were fatal.
Fever of unknown origin was the most common side effect and affected 18 patients, resulting in four fatal cases of sepsis. Eight patients developed pneumonias (one fatal Pneumocystis jirovecii pneumonia (PCP)) and seven patients showed Cytomegalovirus (CMV) infections (two fatal).
A total of 12 patients developed fatal SAEs during therapy or within 6 months after the last cycle has been given, 5 of which were clearly associated with FCCam treatment: One patient died from refractory AIHA after the fifth cycle and one patient with del(17p) developed a necrotizing tonsillitis followed by septic shock after the first cycle. One patient rejected intensive care treatment after developing a pneumonia in addition to a severe Figure 1 . Event-free survival in correlation to del(17p). A total of 10 of 56 patients were found with del(17p). EFS was independent of presence of deletion 17p (P ¼ 0.226). Abbreviations: CR, complete response rate; CRi, CR with incomplete recovery of blood count; CRu, CR unconfirmed by bone marrow biopsy; MRD, minimal residual disease; pB, peripheral blood; n.a., not analyzed; ORR, overall response rate; PD, progredient disease; PR, partial remission; SD, stable disease. CRu and CRi were counted as PR.
Letters to the Editor chronic obstructive pulmonary disease (COPD). Another two patients died of CMV infections, both of which were not sufficiently monitored for reactivation. Three fatal cases were most likely not associated with FCCam, as one patient with known coronary heart disease died due to myocardial infarction, another patient developed multiple brain metastasis of a carcinoma of unknown primary and one patient died after a diverticulitis perforated 6 months after completion of chemoimmunotherapy.
The remaining four documented fatal events happened in patients with progressive CLL, two after initiation of relapse therapy.
As shown in Table 1 , the ORR based on an intention to treat (ITT) analysis including all 57 patients was 56% according to NCI criteria, with 6 (11%) patients achieving a CR. Altogether 26 (45%) patients showed a partial remission, 11 (21%) patients had stable disease and 9 patients did not respond to therapy (17%). Five patients (9%) had no response assessment, as mentioned earlier.
Of note, the results are based on a strict intention to treat analysis including also the patients without response assessment.
Analyzed by subgroups, no significant differences in response were detected according to cytogenetics or IGHV mutational status. Among 11 patients with del(17p), ORR was 80% in 5 untreated patients and 50% in 6 pretreated patients; ORR was 60% for those 45 patients showing an unmutated IGHV.
As expected, response was better for less intensively pretreated patients, resulting in an ORR of 85% for fludarabine monotherapy vs only 42% for FC-or bendamustine plus rituximab (BR)-pretreated patients (20%) and 33% for fludarabine-refractory patients.
After a median observation time of 23 months the median overall survival for all patients was 45 months (95% CI: 22-68 months) with a median EFS of 11 months (95% CI: 8-13 months) and PFS of 17 months (95% CI: 10-25 months). As expected, EFS was dependent on response (Po0.001). Owing to a small number of only 24 patients tested for MRD, only a trend towards a significant difference in EFS based on MRD results could be demonstrated (P ¼ 0.062). Calculated by subgroups, EFS was independent of mutational status (P ¼ 0.104) or presence of deletion 17p (P ¼ 0.226, Figure 1) .
The final results of this phase II trial clearly did not meet our expectations in terms of response and safety. With respect to efficacy, FCCam seemed inferior to other relapse regimens such as FCR and FluCam. 6, 9 More importantly, FCCam induced a higher rate of toxicity including fatal complications clearly related to the treatment in 5 of 57 patients, resulting in an inacceptable treatment-related mortality rate of nearly 9%. One possible explanation for these inferior results with FCCam might have been the patient selection, as most patients have been pretreated with fludarabine containing regimen including rituximab combinations (88%). For those patients being only pretreated with fludarabine (n ¼ 15), the overall response showed to be 85% compared with only 42% in FC-pretreated patients (n ¼ 27). 79% of our patients were IGHV unmutated and 19% of patients showed a del(17), indicating a high-risk population.
On the other hand, a BR combination trial of our group with a similar patient selection showed a similar ORR of 59% with complete remissions (CR) in 9% of patients, but a much better safety profile. 10 In FCCam, 62% of patients tested for MRD in peripheral blood showed to be MRD-negative, compared with only 7.4% in BR-treated patients, likely reflecting preferential clearing of the blood compartment by alemtuzumab.
11
The high-risk features del(17p) or unmutated IGHV did not affect EFS and PFS.
Comparing FluCam with FCCam, it is important to consider that not only the addition of cyclophosphamide might explain the striking differences in the safety profile but also the different routes of administration of alemtuzumab. A subcutaneous administration with 4 weekly intervals is not the approved way of administration, and the correlations of plasma levels of alemtuzumab to response and toxicity are still not well-enough understood.
In conclusion, an ORR of 56% and a treatment-related mortality of 9% do not justify the use of FCCam in unselected, relapsed patients with CLL. Therefore, and in contrast to FluCam, FCCam cannot be recommended as therapy of relapsed or high-risk CLL patient.
Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens The combination of high-dose melphalan supported by autologous stem cell transplantation (ASCT) has significantly increased response rate and survival in patients with multiple myeloma (MM), and is now considered the new standard of care for patients eligible to the transplant procedure. 1 The peripheral blood stem cells (PBSC) collection is preceded by the induction chemotherapy to decrease the tumor mass within the bone marrow, also participating on in vivo purging to decrease the contamination of the stem cell collection with tumor cells. Mobilization and cytapheresis generally takes place following cycle 3 or 4 of induction, and steady state remains considered the easiest and safest way to collect PBSC. 2 The VAD (vincristin-adriamycin-dexamethasone) was the historical induction regimen, before the era of targeted novel agents; 3 however, the bortezomib-based induction therapy has become the gold standard, with increased response rates and prolonged progressionfree survival. 1 The previous studies showed that bortezomib had no toxic effects on stem cells, megakaryocytes or neutrophil precursors, nor on the quality of PBSC as defined by engraftment time, and causes only transient and reversible thrombocytopenia and neutropenia. 4 Nonetheless, we have noticed in-house that the amount of days of collection may increase following bortezomib-dexamethasone (VD) induction as compared with VAD, although the final harvested PBSC amount appeared identical. We have therefore hypothesized that bortezomib-based induction therapy decreased the quality of harvest during the mobilization process, and that might correlate to an increased days of collection and consequently impacted significantly on the cost of the procedure.
We conducted a retrospective study on 112 newly diagnosed MM patients 5 collected from 2006 to 2010 at the Apheresis Department, EFS (Etablissement Franc¸ais du Sang) Nord de France that have received VD (N ¼ 70) or VAD (N ¼ 42) induction regimens. A third group was constituted of 11 patients treated with VTd (bortezomib-thalidomide-low-dose dexamethasone) for use as comparison, as this group was collected using high-dose cyclophosphamide (hdCyclo). 6, 7 We have excluded patients who might have received other bortezomib-based regimens and who were not collected at front line to homogenize our studied population. The median age at collection was 57, 62 and 60 years; sex ratio was 1.64, 1.21 and 1.20; and median weight was 73, 65 and 72 kg for the three groups, respectively. In all, 9%, 17% and 11% had creatinin 420 mg/l, and 59%, 60% and 57% had ISS 2 þ 3, respectively, at diagnosis (P ¼ NS). In all, 3% of patients had platelets o100 g/l in the former group and none in the remaining two groups, and 2%, 7% and 4% had hemoglobin o10 g/dl, respectively, at the time of collection (P ¼ NS). The median number of cycles was 4 (range 1-5) in either group, VD or VAD. The median number of cycles was 3 (range 1-4) in the VTD group. As expected, the response rates were greater in the bortezomib-based induction regimen groups, 79 and 89%, versus 60% using VAD (P ¼ 0.0095) before ASCT. The steady state procedure for the first two groups and the hdCyclo procedure were conducted as published. 2 All harvests were performed on SPECTRA, MNC program (Terumo BCT, Bourg La Reine, France). CFU-GM (colony-forming unit granulocyte and macrophage) was determined as previously published.
8 CD34 þ cells (circulating or in the cytapheresis product) were enumerated on multicolor flow cytometry single platform on a XLMCL Coulter EPICS Cytometer (Beckman Coulter France S.A.S, Villepinte, Roissy CDG Cedex, France), in accordance with the International Society of Hemotherapy and Graft Engineering protocols recommendations. 9, 10 This study was approved by the Ethical Committee of Human Experimentation in Lille, France, and collection of patients data was in accordance with the Helsinki Declaration.
Overall, the mobilization of circulating CD34 þ cells was lower in the VD group as compared with the VAD (Table 1) . We then sought to study whether the lower mobilization rate in the VD group negatively impacted the quantity of PBSC collected during cytapheresis. We observed that the yield of daily harvested CD34 þ cells and CFU-GM count were also lower in the VD group as compared with the VAD (Table 1) , irrespective of the response rate status. The median ( ± s.e.) daily harvest of responders to VD was greater than non-responders, 6.3±0.9 versus 3.6±2.5, although not significant (P ¼ 0.08); but clearly inferior to VAD, 7.8 ± 3.5 and 8.3 ± 2.0, respectively. We also noticed insufficient daily harvest (o2 Â 10 6 CD34/kg) and a lower rate of very satisfactory daily harvests (44 Â 10 6 CD34/kg) in the VD group as compared with the VAD (Figure 1a , Table 1 ). 10 Similar results were observed using the CFU-GM counts. Furthermore, more patients needed more than 2 days of harvest in the VD versus VAD group (Figure 1b, Table 1 ). In contrast, the VTd group had a greater mobilization and daily harvest using hdCyclo, which turned into no insufficient daily harvest and a higher rate of very satisfactory daily harvest, using either CD34/kg or CFU-GM count. We have looked at the response rate that can affect the mobilization and collection yield, being a potential confounding factor to eliminate, but the response rate after induction was clearly superior in the VD group. There was no increase in the infection rate, especially related to dexamethasone. Finally, the percentage of patients with hemoglobin o10 g/dl and platelets o100 g/l at the harvesting time, both criteria considered as predictive markers of poor cytapheresis efficiency, did not differ in the VD and VAD groups. 11 There is no clear explanation on why bortezomib has some negative impact on mobilization and collection. Bortezomib is not known as a myelotoxic drug, which could negatively affect Accepted article preview online 25 May 2012; advance online publication, 19 June 2012
